Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42


Amino acid sequence conservation of the algesic fragment of myelin basic protein is required for its interaction with CDK5 and function in pain.

Chernov AV, Remacle AG, Hullugundi SK, Cieplak P, Angert M, Dolkas J, Shubayev VI, Strongin AY.

FEBS J. 2018 Sep;285(18):3485-3502. doi: 10.1111/febs.14623. Epub 2018 Aug 27.


Interaction of the cryptic fragment of myelin basic protein with mitochondrial voltage-dependent anion-selective channel-1 affects cell energy metabolism.

Remacle AG, Hullugundi SK, Dolkas J, Angert M, Cieplak P, Scott D, Chernov AV, Shubayev VI, Strongin AY.

Biochem J. 2018 Jul 31;475(14):2355-2376. doi: 10.1042/BCJ20180137.


Acute- and late-phase matrix metalloproteinase (MMP)-9 activity is comparable in female and male rats after peripheral nerve injury.

Remacle AG, Hullugundi SK, Dolkas J, Angert M, Chernov AV, Strongin AY, Shubayev VI.

J Neuroinflammation. 2018 Mar 20;15(1):89. doi: 10.1186/s12974-018-1123-7.


A sensitive and selective ELISA methodology quantifies a demyelination marker in experimental and clinical samples.

Remacle AG, Dolkas J, Angert M, Hullugundi SK, Chernov AV, Jones RCW 3rd, Shubayev VI, Strongin AY.

J Immunol Methods. 2018 Apr;455:80-87. doi: 10.1016/j.jim.2018.02.002. Epub 2018 Feb 8.


Directed Evolution to Engineer Monobody for FRET Biosensor Assembly and Imaging at Live-Cell Surface.

Limsakul P, Peng Q, Wu Y, Allen ME, Liang J, Remacle AG, Lopez T, Ge X, Kay BK, Zhao H, Strongin AY, Yang XL, Lu S, Wang Y.

Cell Chem Biol. 2018 Apr 19;25(4):370-379.e4. doi: 10.1016/j.chembiol.2018.01.002. Epub 2018 Jan 27.


Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries.

Nam DH, Rodriguez C, Remacle AG, Strongin AY, Ge X.

Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):14970-14975. doi: 10.1073/pnas.1609375114. Epub 2016 Dec 13.


Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis.

Remacle AG, Cieplak P, Nam DH, Shiryaev SA, Ge X, Strongin AY.

Oncotarget. 2017 Jan 10;8(2):2781-2799. doi: 10.18632/oncotarget.13157.


Reciprocal relationship between membrane type 1 matrix metalloproteinase and the algesic peptides of myelin basic protein contributes to chronic neuropathic pain.

Hong S, Remacle AG, Shiryaev SA, Choi W, Hullugundi SK, Dolkas J, Angert M, Nishihara T, Yaksh TL, Strongin AY, Shubayev VI.

Brain Behav Immun. 2017 Feb;60:282-292. doi: 10.1016/j.bbi.2016.11.003. Epub 2016 Nov 7.


The alternatively spliced fibronectin CS1 isoform regulates IL-17A levels and mechanical allodynia after peripheral nerve injury.

Liu H, Dolkas J, Hoang K, Angert M, Chernov AV, Remacle AG, Shiryaev SA, Strongin AY, Nishihara T, Shubayev VI.

J Neuroinflammation. 2015 Sep 4;12:158. doi: 10.1186/s12974-015-0377-6.


Matrix Metalloproteinase (MMP) Proteolysis of the Extracellular Loop of Voltage-gated Sodium Channels and Potential Alterations in Pain Signaling.

Remacle AG, Kumar S, Motamedchaboki K, Cieplak P, Hullugundi S, Dolkas J, Shubayev VI, Strongin AY.

J Biol Chem. 2015 Sep 18;290(38):22939-44. doi: 10.1074/jbc.C115.671107. Epub 2015 Aug 17.


High-Throughput Multiplexed Peptide-Centric Profiling Illustrates Both Substrate Cleavage Redundancy and Specificity in the MMP Family.

Kukreja M, Shiryaev SA, Cieplak P, Muranaka N, Routenberg DA, Chernov AV, Kumar S, Remacle AG, Smith JW, Kozlov IA, Strongin AY.

Chem Biol. 2015 Aug 20;22(8):1122-33. doi: 10.1016/j.chembiol.2015.07.008. Epub 2015 Aug 6.


Matrix metalloproteinase-14 both sheds cell surface neuronal glial antigen 2 (NG2) proteoglycan on macrophages and governs the response to peripheral nerve injury.

Nishihara T, Remacle AG, Angert M, Shubayev I, Shiryaev SA, Liu H, Dolkas J, Chernov AV, Strongin AY, Shubayev VI.

J Biol Chem. 2015 Feb 6;290(6):3693-707. doi: 10.1074/jbc.M114.603431. Epub 2014 Dec 8.


Distinct interactions with cellular E-cadherin of the two virulent metalloproteinases encoded by a Bacteroides fragilis pathogenicity island.

Remacle AG, Shiryaev SA, Strongin AY.

PLoS One. 2014 Nov 20;9(11):e113896. doi: 10.1371/journal.pone.0113896. eCollection 2014.


Structural and functional diversity of metalloproteinases encoded by the Bacteroides fragilis pathogenicity island.

Shiryaev SA, Aleshin AE, Muranaka N, Kukreja M, Routenberg DA, Remacle AG, Liddington RC, Cieplak P, Kozlov IA, Strongin AY.

FEBS J. 2014 Jun;281(11):2487-502. doi: 10.1111/febs.12804. Epub 2014 Apr 22.


A monoclonal antibody interferes with TIMP-2 binding and incapacitates the MMP-2-activating function of multifunctional, pro-tumorigenic MMP-14/MT1-MMP.

Shiryaev SA, Remacle AG, Golubkov VS, Ingvarsen S, Porse A, Behrendt N, Cieplak P, Strongin AY.

Oncogenesis. 2013 Dec 2;2:e80. doi: 10.1038/oncsis.2013.44.


Substrate cleavage profiling suggests a distinct function of Bacteroides fragilis metalloproteinases (fragilysin and metalloproteinase II) at the microbiome-inflammation-cancer interface.

Shiryaev SA, Remacle AG, Chernov AV, Golubkov VS, Motamedchaboki K, Muranaka N, Dambacher CM, Capek P, Kukreja M, Kozlov IA, Perucho M, Cieplak P, Strongin AY.

J Biol Chem. 2013 Nov 29;288(48):34956-67. doi: 10.1074/jbc.M113.516153. Epub 2013 Oct 21.


Non-destructive and selective imaging of the functionally active, pro-invasive membrane type-1 matrix metalloproteinase (MT1-MMP) enzyme in cancer cells.

Remacle AG, Shiryaev SA, Golubkov VS, Freskos JN, Brown MA, Karwa AS, Naik AD, Howard CP, Sympson CJ, Strongin AY.

J Biol Chem. 2013 Jul 12;288(28):20568-80. doi: 10.1074/jbc.M113.471508. Epub 2013 Jun 3.


Immunodominant fragments of myelin basic protein initiate T cell-dependent pain.

Liu H, Shiryaev SA, Chernov AV, Kim Y, Shubayev I, Remacle AG, Baranovskaya S, Golubkov VS, Strongin AY, Shubayev VI.

J Neuroinflammation. 2012 Jun 7;9:119. doi: 10.1186/1742-2094-9-119.


The MMP-9/TIMP-1 axis controls the status of differentiation and function of myelin-forming Schwann cells in nerve regeneration.

Kim Y, Remacle AG, Chernov AV, Liu H, Shubayev I, Lai C, Dolkas J, Shiryaev SA, Golubkov VS, Mizisin AP, Strongin AY, Shubayev VI.

PLoS One. 2012;7(3):e33664. doi: 10.1371/journal.pone.0033664. Epub 2012 Mar 16.


Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth.

Remacle AG, Golubkov VS, Shiryaev SA, Dahl R, Stebbins JL, Chernov AV, Cheltsov AV, Pellecchia M, Strongin AY.

Cancer Res. 2012 May 1;72(9):2339-49. doi: 10.1158/0008-5472.CAN-11-4149. Epub 2012 Mar 9.


Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases by tissue inhibitors of metalloproteinases.

Remacle AG, Shiryaev SA, Radichev IA, Rozanov DV, Stec B, Strongin AY.

J Biol Chem. 2011 Jun 10;286(23):21002-12. doi: 10.1074/jbc.M110.200139. Epub 2011 Apr 25.


A femtomol range FRET biosensor reports exceedingly low levels of cell surface furin: implications for the processing of anthrax protective antigen.

Gawlik K, Remacle AG, Shiryaev SA, Golubkov VS, Ouyang M, Wang Y, Strongin AY.

PLoS One. 2010 Jun 24;5(6):e11305. doi: 10.1371/journal.pone.0011305.


Biochemical characterization of the cellular glycosylphosphatidylinositol-linked membrane type-6 matrix metalloproteinase.

Radichev IA, Remacle AG, Shiryaev SA, Purves AN, Johnson SL, Pellecchia M, Strongin AY.

J Biol Chem. 2010 May 21;285(21):16076-86. doi: 10.1074/jbc.M110.107094. Epub 2010 Mar 22.


Simultaneous visualization of protumorigenic Src and MT1-MMP activities with fluorescence resonance energy transfer.

Ouyang M, Huang H, Shaner NC, Remacle AG, Shiryaev SA, Strongin AY, Tsien RY, Wang Y.

Cancer Res. 2010 Mar 15;70(6):2204-12. doi: 10.1158/0008-5472.CAN-09-3698. Epub 2010 Mar 2.


Selective and potent furin inhibitors protect cells from anthrax without significant toxicity.

Remacle AG, Gawlik K, Golubkov VS, Cadwell GW, Liddington RC, Cieplak P, Millis SZ, Desjardins R, Routhier S, Yuan XW, Neugebauer WA, Day R, Strongin AY.

Int J Biochem Cell Biol. 2010 Jun;42(6):987-95. doi: 10.1016/j.biocel.2010.02.013. Epub 2010 Mar 1.


Inflammatory proprotein convertase-matrix metalloproteinase proteolytic pathway in antigen-presenting cells as a step to autoimmune multiple sclerosis.

Shiryaev SA, Remacle AG, Savinov AY, Chernov AV, Cieplak P, Radichev IA, Williams R, Shiryaeva TN, Gawlik K, Postnova TI, Ratnikov BI, Eroshkin AM, Motamedchaboki K, Smith JW, Strongin AY.

J Biol Chem. 2009 Oct 30;284(44):30615-26. doi: 10.1074/jbc.M109.041244. Epub 2009 Sep 2.


Timp-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells.

Sounni NE, Rozanov DV, Remacle AG, Golubkov VS, Noel A, Strongin AY.

Int J Cancer. 2010 Mar 1;126(5):1067-78. doi: 10.1002/ijc.24690. Erratum in: Int J Cancer. 2010 Apr 15;126(8):2002.


Autocatalytic activation of the furin zymogen requires removal of the emerging enzyme's N-terminus from the active site.

Gawlik K, Shiryaev SA, Zhu W, Motamedchaboki K, Desjardins R, Day R, Remacle AG, Stec B, Strongin AY.

PLoS One. 2009;4(4):e5031. doi: 10.1371/journal.pone.0005031. Epub 2009 Apr 7.


Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells.

Chernov AV, Sounni NE, Remacle AG, Strongin AY.

J Biol Chem. 2009 May 8;284(19):12727-34. doi: 10.1074/jbc.M900273200. Epub 2009 Mar 13.


Biochemical evidence of the interactions of membrane type-1 matrix metalloproteinase (MT1-MMP) with adenine nucleotide translocator (ANT): potential implications linking proteolysis with energy metabolism in cancer cells.

Radichev IA, Remacle AG, Sounni NE, Shiryaev SA, Rozanov DV, Zhu W, Golubkova NV, Postnova TI, Golubkov VS, Strongin AY.

Biochem J. 2009 Apr 28;420(1):37-47. doi: 10.1042/BJ20090082.


Substrate cleavage analysis of furin and related proprotein convertases. A comparative study.

Remacle AG, Shiryaev SA, Oh ES, Cieplak P, Srinivasan A, Wei G, Liddington RC, Ratnikov BI, Parent A, Desjardins R, Day R, Smith JW, Lebl M, Strongin AY.

J Biol Chem. 2008 Jul 25;283(30):20897-906. doi: 10.1074/jbc.M803762200. Epub 2008 May 27.


Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism.

D'Alessio S, Ferrari G, Cinnante K, Scheerer W, Galloway AC, Roses DF, Rozanov DV, Remacle AG, Oh ES, Shiryaev SA, Strongin AY, Pintucci G, Mignatti P.

J Biol Chem. 2008 Jan 4;283(1):87-99. Epub 2007 Nov 8.


Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens.

Shiryaev SA, Remacle AG, Ratnikov BI, Nelson NA, Savinov AY, Wei G, Bottini M, Rega MF, Parent A, Desjardins R, Fugere M, Day R, Sabet M, Pellecchia M, Liddington RC, Smith JW, Mustelin T, Guiney DG, Lebl M, Strongin AY.

J Biol Chem. 2007 Jul 20;282(29):20847-53. Epub 2007 May 30.


Furin regulates the intracellular activation and the uptake rate of cell surface-associated MT1-MMP.

Remacle AG, Rozanov DV, Fugere M, Day R, Strongin AY.

Oncogene. 2006 Sep 14;25(41):5648-55. Epub 2006 Apr 24.


O-glycosylation regulates autolysis of cellular membrane type-1 matrix metalloproteinase (MT1-MMP).

Remacle AG, Chekanov AV, Golubkov VS, Savinov AY, Rozanov DV, Strongin AY.

J Biol Chem. 2006 Jun 23;281(25):16897-905. Epub 2006 Apr 20.


Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients.

Savinov AY, Remacle AG, Golubkov VS, Krajewska M, Kennedy S, Duffy MJ, Rozanov DV, Krajewski S, Strongin AY.

Cancer Res. 2006 Mar 1;66(5):2716-24.


Both PA63 and PA83 are endocytosed within an anthrax protective antigen mixed heptamer: a putative mechanism to overcome a furin deficiency.

Chekanov AV, Remacle AG, Golubkov VS, Akatov VS, Sikora S, Savinov AY, Fugere M, Day R, Rozanov DV, Strongin AY.

Arch Biochem Biophys. 2006 Feb 1;446(1):52-9. Epub 2005 Dec 7.


The transmembrane domain is essential for the microtubular trafficking of membrane type-1 matrix metalloproteinase (MT1-MMP).

Remacle AG, Rozanov DV, Baciu PC, Chekanov AV, Golubkov VS, Strongin AY.

J Cell Sci. 2005 Nov 1;118(Pt 21):4975-84. Epub 2005 Oct 11.


Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.

Remacle AG, Noël A, Duggan C, McDermott E, O'Higgins N, Foidart JM, Duffy MJ.

Br J Cancer. 1998 Mar;77(6):926-31.


Purification of progelatinases A and B by continuous-elution electrophoresis.

Remacle AG, Baramova EN, Weidle UH, Krell HW, Foidart JM.

Protein Expr Purif. 1995 Aug;6(4):417-22.


Tumor cell surface-associated binding site for the M(r) 72,000 type IV collagenase.

Emonard HP, Remacle AG, Noël AC, Grimaud JA, Stetler-Stevenson WG, Foidart JM.

Cancer Res. 1992 Oct 15;52(20):5845-8.

Supplemental Content

Loading ...
Support Center